The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ELCC 2016 | Biomarkers and lung cancer: Current status

Name: Biomarkers and lung cancer: Current status
Uploaded: 2016-04-15T00:00:00.000Z
Duration: 1 min 9 s
Description: At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Keith Kerr, BSc, MB ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, United Kingdom, discusses biomarker-based selection of therapy and the progress in understanding clinically relevant biomarkers in patients with lung cancer.

Keith Kerr • 15 Apr 2016

ELCC 2016

Lung Cancer

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Keith Kerr, BSc, MB ChB, FRCPath, FRCPE, from the University of Aberdeen, Aberdeen, United Kingdom, discusses biomarker-based selection of therapy and the progress in understanding clinically relevant biomarkers in patients with lung cancer.